News from vanda pharmaceuticals inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 25, 2023, 07:00 ET Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its Phase III study of tradipitant in motion sickness, confirming...

May 10, 2023, 14:26 ET Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its Hetlioz® Abbreviated New Drug Application appeal. Today a...

May 04, 2023, 18:00 ET Vanda Pharmaceuticals Announces Presentations at DDW 2023

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL and...

May 03, 2023, 16:01 ET Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2023. "The...

May 02, 2023, 12:46 ET Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its action against the federal government for the uncompensated taking and misuse...

Apr 27, 2023, 18:00 ET Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2023 on Wednesday, May 3, 2023, after ...

Mar 28, 2023, 13:26 ET Vanda Prevails in Jet Lag Litigation Against the FDA

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced a win in its jet lag FOIA litigation against the FDA. On March 27, 2023 a federal...

Mar 17, 2023, 07:00 ET Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective...

Feb 08, 2023, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended...

Feb 01, 2023, 18:30 ET Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday,...

Jan 06, 2023, 09:00 ET Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San...

Dec 19, 2022, 07:00 ET Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt® (iloperidone tablets), a...

Dec 16, 2022, 14:54 ET Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ® ANDA litigation ruling. On December...

Dec 13, 2022, 15:15 ET Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ® ANDA Litigation. Vanda has brought several...

Dec 02, 2022, 07:00 ET Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7...

Nov 08, 2022, 20:30 ET Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in ...

Nov 02, 2022, 16:01 ET Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2022....

Oct 26, 2022, 18:00 ET Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022,...

Oct 21, 2022, 14:00 ET Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for ...

Sep 29, 2022, 16:30 ET Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) (KOSDAQ: 24460) today announced that they have entered into a...

Sep 08, 2022, 18:00 ET Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment...

Sep 07, 2022, 18:38 ET VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug...

Aug 03, 2022, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022....

Jul 27, 2022, 17:30 ET Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022,...

Jun 02, 2022, 16:30 ET Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare...